drug · small molecule
patient view →imatinib mesylate
Phase 2updated 2mo agoby $IKT Inhibikase Therapeutics, Inc.🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for chronic myelogenous leukemia and 55 investigational indications.
targets
Bcr/Abl fusion proteinMast/stem cell growth factor receptor KitPlatelet-derived growth factor receptor betaTyrosine-protein kinase ABL1
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that